Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(150 sites)

United States

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

City of Hope Comprehensive Cancer Center, Duarte, California

Kaiser Permanente Dublin, Dublin, California

Kaiser Permanente-Fremont, Fremont, California

Kaiser Permanente Fresno Orchard Plaza, Fresno, California